Evaluation of CD16, CD32, CD40, and CD152 polymorphisms in immune thrombocytopenia patients: a systematic review, meta-analysis, and trial sequential analysis - Takeaways - MDSpire

Evaluation of CD16, CD32, CD40, and CD152 polymorphisms in immune thrombocytopenia patients: a systematic review, meta-analysis, and trial sequential analysis

  • By

  • Yan Pan

  • Fangjian Chen

  • Yanzhong Wang

  • June 23, 2026

  • 0 min

Share

  • 1

    This study investigates genetic polymorphisms in CD16, CD32, CD40, and CD152 related to immune thrombocytopenia (ITP).

  • 2

    Thirty-three studies were included in the meta-analysis, focusing on the association of specific genetic variants with ITP.

  • 3

    The FcγRIIIA-158 F/V polymorphism showed a significant association with ITP, with an odds ratio of 2.61 in the homozygous framework.

  • 4

    No significant associations were found for other polymorphisms, including FcγRIIA-131 H/R and CD40 variants.

  • 5

    The study highlights the need for further research to confirm the findings regarding genetic variants and ITP susceptibility.

Original Source(s)

Evaluation of CD16, CD32, CD40, and CD152 polymorphisms in immune thrombocytopenia patients: a systematic review, meta-analysis, and trial sequential analysis

  • by Yan Pan, Fangjian Chen, Yanzhong Wang

  • June 23, 2026

Related Content

The quiet joy of being an oncologist

Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study

The application of rituximab during the conditioning regimen prevents Epstein - Barr virus infection following rATG-based haploidentical hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis